| Filed On | Filing |
|---|---|
| 16 Nov 2026 |
Form 4: Morich Frank, Director
Bought 15,000 shares ($15K) |
| 16 Nov 2026 |
Form 4: Williamson Robert F Iii, Director
Bought 24,898 shares ($20.9K) |
| 16 Nov 2026 |
Form 4: Woods Lori A, Director
Bought 23,750 shares ($20K) |
| 13 Nov 2026 |
Form 4: Puhlmann Markus, Chief Medical Officer
Bought 6,000 shares ($4.98K) · Bought 35,000 shares ($29.6K) |
| 12 Nov 2026 | SCHEDULE 13D/A |
| 12 Nov 2026 |
Form 4: Spoor Johan M., Director
Bought 47,000 shares ($37.9K) |
| 10 Nov 2026 | SCHEDULE 13G |
| 09 Nov 2026 | 10-Q |
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition; Other Events
Updated interim data from the Phase 1/2a bamzireotide navoxetan (VMT-α-NET) presentations continue to support an emerging therapeutic window and potential to achieve a best-in-class profile in NETs |
| 06 Nov 2026 |
8-K: Other Events
Perspective Therapeutics Presents Promising [212Pb]Lapemelanotide Zapixetar (VMT01) Monotherapy Data from a Phase 1/2a Study in Heavily Pretreated Advanced Melanoma Patients at SITC 2026 |
| 06 Nov 2026 |
8-K: Other Events
Perspective Therapeutics Presents Encouraging Incremental Data and Analyses from Phase 1/2a Trial of [212Pb]Bamzireotide Navoxetan (VMT-α-NET) in Advanced SSTR2 Expressing NETs |
| 23 Oct 2026 |
8-K: Other Events
Perspective’s [212Pb]Bamzireotide Navoxetan (VMT-α-NET) Demonstrates Encouraging Safety, Durable Disease Control, and Robust Tumor Response Across Multiple Dose Cohorts in Phase 1/2a Trial in Advanced SSTR2-Expressing NETs |
| 08 Oct 2026 |
8-K: Other Events
Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors |
| 01 Oct 2026 |
8-K: Other Events
Next-Generation Radiopharmaceuticals Redefining Targeted Oncology |
| 23 Sep 2026 | SCHEDULE 13D/A |
| 14 Sep 2026 |
8-K: Other Events
Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors |
| 08 Sep 2026 |
8-K: Other Events
Next-Generation Radiopharmaceuticals Redefining Targeted Oncology |
| 08 Sep 2026 |
Form 4: Lantheus Alpha Therapy, Llc, 10% owner and 1 other
Sold 80,783 shares ($251K) · Sold 167,149 shares ($526K) |
| 04 Sep 2026 |
Form 4: Lantheus Alpha Therapy, Llc, 10% owner and 1 other
Sold 42,129 shares ($131K) |
| 04 Sep 2026 |
Form 4: Lantheus Alpha Therapy, Llc, 10% owner
Sold 78,145 shares ($246K) · Sold 35,769 shares ($112K) |
Loading...